产品
编 号：F194492
分子式：C10H10Br2N4OS
分子量：394.09
分子式：C10H10Br2N4OS
分子量：394.09
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1621375-32-3
产品详情
生物活性：
VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer.
体内研究：
在 LNCaP 异种移植模型中，VPC-14449 (100 mg/kg；每天腹腔注射两次，持续 4 周) 在总持续时间为 4 周的情况下减小肿瘤体积并消除 PSA 产生，且体重没有降低。Animal Model:Nude mice (Harlan Sprague-Dawley; 25-31 g; 6-8 weeks) were subcutaneously inoculated with LNCaP cells and castrated
Dosage:100 mg/kg
Administration:I.p. twice daily for 4 weeks
Result:Suppressed LNCaP tumor volume and blocked serum PSA production.
体外研究：
VPC-14449 (0.01-100 μM；24 小时) 抑制 LNCaP、C4-2、MR49F 和 22Rv1 细胞中的 AR 转录活性和细胞活力。 VPC-14449 (0.01-100 μM；24 h) 剂量依赖性地抑制 PC3 细胞中瞬时表达的全长人 AR (IC50=0.34 μM) 而不影响 AR 蛋白表达。
VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer.
体内研究：
在 LNCaP 异种移植模型中，VPC-14449 (100 mg/kg；每天腹腔注射两次，持续 4 周) 在总持续时间为 4 周的情况下减小肿瘤体积并消除 PSA 产生，且体重没有降低。Animal Model:Nude mice (Harlan Sprague-Dawley; 25-31 g; 6-8 weeks) were subcutaneously inoculated with LNCaP cells and castrated
Dosage:100 mg/kg
Administration:I.p. twice daily for 4 weeks
Result:Suppressed LNCaP tumor volume and blocked serum PSA production.
体外研究：
VPC-14449 (0.01-100 μM；24 小时) 抑制 LNCaP、C4-2、MR49F 和 22Rv1 细胞中的 AR 转录活性和细胞活力。 VPC-14449 (0.01-100 μM；24 h) 剂量依赖性地抑制 PC3 细胞中瞬时表达的全长人 AR (IC50=0.34 μM) 而不影响 AR 蛋白表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备